Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing

Doshi, Peter

dc.contributor.author	Doshi, Peter
dc.date.accessioned	2017-05-24T13:47:18Z
dc.date.available	2017-05-24T13:47:18Z
dc.date.issued	2016-01-06
dc.identifier.citation	Doshi, P. (2016). Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing. BMJ, 352. DOI: 10.1136/bmj.h6849
dc.identifier.uri	http://hdl.handle.net/10713/6584
dc.description	Author discusses the question, "Will outsourcing determination of antibiotic effectiveness allow drug companies to influence prescribing?"
dc.description.uri	http://bmj.com/cgi/content/full/bmj.h6849?ijkey=ThkkcYTig2AlYyn&keytype=ref
dc.language.iso	en_US	en_US
dc.publisher	BMJ Publishing Group	en_US
dc.subject	National Physicians Alliance FDA Task Force	en_US
dc.subject	21st Century Cures Act	en_US
dc.subject.lcsh	Clinical and Laboratory Standards Institute	en_US
dc.subject.lcsh	United States. Food and Drug Administration	en_US
dc.subject.mesh	Conflict of Interest	en_US
dc.subject.mesh	Microbial Sensitivity Tests--standards	en_US
dc.subject.mesh	Outsourced Services--standards	en_US
dc.title	Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing	en_US
dc.type	Article	en_US
dc.identifier.doi	10.1136/bmj.h6849
dc.identifier.pmid	26740024
dc.description.uriname	Click here for the free full-text article on publisher's website	en_US
refterms.dateFOA	2019-02-19T18:15:22Z